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Introduzione. La terapia di re sincronizzazione cardiaca (RCT) si è dimostrata efficace nel 
trattamento dei pazienti con scompenso cardiaco e blocco di branca sinistro (BBSn). 
Recentemente sono stati proposti nuovi criteri ECG per definire il BBSn. Questi criteri 
sono più restrittivi rispetto a quelli utilizzati nella definizione dell’American Heart 
Association (AHA), incrementando la specificità della diagnosi di BBSn. In questo studio 
abbiamo determinato la risposta alla RCT in termini ecocardiografici in pazienti che 
rispettvano (Strict-LBBB) o no (Traditional-LBBB)  la nuova definizione di BBSn. 
Metodi. Abbiamo arruolato pazienti consecutivi sottoposti ad impianto di RCT (pacemaker 
o defibrillatore) inclusi nel Regustro CRT MORE. Sono stati esclusi dall’analisi pazienti che 
non rispettavano i criteri di BBSn secondo la definzione dell’AHA, fibrillazione atriale, 
blocco di branca destro e già portatori di pacemaker. Strict-LBBB è stato definito come: 
QRS ≥140ms per I maschi e ≥130ms per le femmine, QS o rS in V1–V2, mid-QRS 
notching o slurring in ≥2 derivazioni contigue. I pazienti che hanno dimostrato una 
riduzione relativa ≥15% del volume telesistiolico ventricolare sinistro (VTS) a 12 mesi sono 
stati definiti “responder”. 
Results. Tra 335 pazienti con BBSn second la definizione LBBB, 131 (39%) presentavano 
Strict-LBBB. I pazienti com e senza Strict-LBBB presentavano caratteristiche cliniche ed 
elettrocardiografiche simili a parte la durata del QRS (166±20ms vs 152±25ms, p<0.001). 
Al controllo a 12 mesi sono risultati “responder” 205 (61%) pazienti: 85 (65%) pazienti con 
Strict-LBBB e 120 (59%) con Traditional-LBBB (p=0.267). All’analisi multivariata, la storia 
di fibrillazione atriale, il VTS più grande, e la presenza di mid-QRS notching in ≥1 
derivazione (OR 1.96; 95%CI 1.04 to 3.70, p=0.038) sono risultati indipendentemente 
associati alla risposta ecocardiografica.  
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ConclusionI. La definizione più restrittiva di BBSn recentemente proposta non migliora 
l’identificazione dei pazienti responder” alla RCT rispetto alla definizone dell’AHA. Tra le 
variabili elettrocardiografiche, solo la presenza di mid-QRS notching in almeno una 









Background. Cardiac resynchronization therapy (CRT) was proved to be effective in 
patients with heart failure and left bundle branch block (LBBB). Recently, new ECG criteria 
have been proposed for the diagnosis of LBBB. These criteria are stricter than the current 
American Heart Association (AHA) criteria and thus increase the specificity of LBBB 
diagnosis. We assessed the rate of echocardiographic response to CRT in patients who 
did and did not meet new criteria (Strict-LBBB). 
Methods. Consecutive patients who received CRT defibrillators were enrolled in the CRT 
MORE registry. Patients with no-LBBB QRS morphology according to AHA, atrial 
fibrillation, right bundle branch block and right ventricular pacing were excluded from the 
analysis. Strict-LBBB was defined as: QRS ≥140ms for men and ≥130ms for women, QS 
or rS in V1–V2, mid-QRS notching or slurring in ≥2 contiguous leads. Patients showing a 
relative decrease of ≥15% in left ventricular end systolic volume (LVESV) at 12 months 
were defined as responders. 
Results. Among 335 patients with AHA LBBB, 131 (39%) had Strict-LBBB. Patients with 
and without Strict-LBBB showed comparable baseline characteristics except for QRS 
duration (166±20ms vs 152±25ms, p<0.001). At 12-month evaluation responders were 205 
(61%). 85 (65%) patients had Strict-LBBB and 120 (59%) had no Strict-LBBB (p=0.267). 
On multivariate analysis, history of atrial fibrillation, larger LVESV, and presence of mid-
QRS notching in ≥1 lead (OR 1.96; 95%CI 1.04 to 3.70, p=0.038) were independently 
associated with the echocardiographic response.  
Conclusions. Recently proposed stricter criteria for LBBB diagnosis did not improve the 
identification of CRT responders. Among ECG variables, only the presence of mid-QRS 










Epidemiology of heart failure  
Approximately 2% of the adult population in developed countries has heart failure (HF); 
most patients will be aged >70 years and about half will have a left ventricular (LV) 
ejection fraction (EF) < 50%.[1] About 1% of emergency hospital admissions amongst 
adults are primarily due to heart failure, which contributes to a further 4%, although these 
may be underestimated due to issues with diagnosis and case definition.w81 In the 
EuroHeart Failure survey, 36% of those who had LV function assessed had an LVEF ≤ 
35% and, of these, 41% had a QRS duration ≥120 ms; 7% had RBBB, 34% had LBBB or 
other intraventricular conduction delay (IVCD) and 17% had QRS ≥150 ms.[2] In the Italian 
Network on CHF (IN-CHF) registry, 1391 patients (25%) had complete LBBB, 336 (6%) 
had complete RBBB and 339 (6%) had other forms of IVCD.[3] The annual incidence of 
LBBB is about10% in ambulatory patients with LV systolic dysfunction and chronic HF.[4] 
Based on current guideline criteria,[5] only a small proportion of patients with HF (perhaps 
5–10%) are indicated for cardiac resynchronization therapy (CRT) but this is still a large 
number of patients. Based on data from two EuroHeart Failure surveys and extrapolating 
from hospital discharge statistics,[2,6,7] it could be estimated that about 400 patients per 
million population per year might be suitable for CRT, or up to 400,000 patients per year in 
ESC countries.  
 The prognosis of HF is generally poor. Of patients admitted to hospital with HF, the one-
year mortality is about 20% in those aged < 75 years and > 40% if aged > 75 years, 
despite contemporary pharmacological therapy.[8-9] High-quality information on the 
prognosis of outpatient populations with HF is harder to find. Patients in clinical trials tend 
to be younger and with fewer co-morbidities than in clinical practice and consequently 
have a better prognosis, with an annual mortality of 5–10% in recent trials, even though 
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the trial protocols excluded very-low-risk patients.[10,11] However, treatment appears to 
have remarkably improved the prognosis of patients with chronic HF over the last 20 
years. For example, the median life expectancy of patients enrolled in the Vasodilator in 
HEart Failure Trial V-HeFT-I trial (study period 1980–85), was just 3.5 years compared 
with more than 8 years for an age-equivalent population with moderately severe heart 
failure, treated with pharmacological therapy plus CRT, enrolled in CArdiac 
REsynchronization in Heart Failure (CARE-HF; study period 2001–2009).[12-14] An ESC 
survey found that patients who received a CRT device had a one-year mortality of 
,10%.[15] Patients with a broad QRS complex have even a worse prognosis that may only 
be partially explained by having a lower LVEF.[2,3,17 –18] In the ICD arm of the 
Multicenter Automatic Defibrillator Trial (MADIT) CRT study, the patients with IVCD, RBBB 
and LBBB had 3-year mortality rates of 4, 7 and 8%, respectively.[19] 
Atrial fibrillation (AF) is the most common arrhythmia in patients with HF. The EuroHeart 
Failure survey reported that up to 45% of patients with HF also presented with intermittent 
or permanent AF.[2] In chronic HF, the prevalence of AF is linked directly to disease 
severity, ranging from10–20% in mild-to-moderate CHF up to 50% in patients with 
advanced disease.[20] AF is a common cause of worsening HF and complicates 
management. Incident AF is associated with a worse prognosis but it is unclear whether 
patients with chronic AF have a worse prognosis than those in sinus rhythm, after 
correcting for age and co-morbidity.[21-26]w100–w105 AF may simply be a marker of 
more severe disease.  
Cardiac dyssynchrony is complex and multifaceted. Prolongation of the atrio-ventricular 
(AV) interval delays systolic contraction, which might then encroach on early diastolic 
filling.[27] Atrial pressure falls as the atria relax. If ventricular contraction is delayed, then 
left ventricular (LV) diastolic pressures will exceed atrial pressure causing diastolic mitral 
regurgitation. The loss of ventricular pre-load then leads to a reduction in LV contractility, 
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due to loss of the Starling mechanism. Both inter- and intra-ventricular conduction delays 
lead to asynchronous contraction of LV wall regions (ventricular dyssynchrony), impairing 
cardiac efficiency and reducing stroke volume and systolic blood pressure. Poorly 
coordinated papillary muscle function may cause or aggravate functional systolic mitral 
regurgitation. Impaired performance promotes adverse LV remodelling. Cardiac 
resynchronization therapy helps to restore AV, inter- and intra-ventricular synchrony, 
improving LV function, reducing functional mitral regurgitation and inducing LV reverse 
remodelling, as evidenced by increases in LV filling time and LVEF, and decreases in LV 
end-diastolic- and end-systolic volumes, mitral regurgitation and septal dyskinesis.[28] The 
dominant mechanism of benefit is likely to vary from one patient to the next and within an 
individual patient over time. It is possible that no single measure will accurately predict the 
response to CRT, since the mechanism of benefit is so heterogeneous.[29-30] 
 History of CRT 
CRT is an established treatment in patients with HF and ventricular conduction delay 
[31,32], especially in the form of left bundle branch block (LBBB) [33-37] in patients with 
New York Heart Association (NYHA) class III HF from a series of RCTs (Figure 1). This 
therapy aims to restore electrical and mechanical synchrony throughout the LV, thus 
improving cardiac function and reducing HF hospitalizations and death [33-36, 38].  
The first randomized trials demonstrated the benefits of CRT on symptoms, exercise 
capacity and LV structure and function.[39-43] The CARE-HF and Comparison of Medical 
Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trials evaluated the 
effects of CRT-P on HF hospitalizations and all-cause mortality.[44-45] A recent meta-
analysis showed that, in these patients, CRT improved symptoms and reduced all-cause 
mortality by 22% and HF hospitalizations by 35%[46] The evidence among NYHA class IV 
heart failure patients is limited, due to the low number of patients enrolled in RCTs (from 7 
to 15%). In a sub-study of the COMPANION trial,w110 class IV patients who had had no 
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scheduled or unscheduled HF hospitalizations during the last month (termed ‘ambulatory’ 
class IV) showed a significant reduction in the combined primary endpoint of time to all-
cause mortality and hospitalization, but only a trend for all-cause mortality and HF deaths.  
Four RCTs have demonstrated that CRT improves LV function, all cause mortality and HF 
hospitalizations of patients with mild HF symptoms (NYHA class I–II), sinus rhythm, LVEF 
≤30–40% and QRS duration ≥120–130 ms.[47-50] However, improvement in functional 
status or quality of life among patients randomized to 
CRT were modest and not robust. Most patients enrolled had NYHA class II HF 
symptoms; only 15% in Resynchronization reVErses Remodelling in Systolic left 
vEntricular dysfunction (REVERSE) and 18% in MADIT-CRT were in NYHA class I.[47,49] 
CRT did not reduce all-cause mortality or HF events among 
NYHA class I patients. Therefore, the recommendation is restricted to patients in NYHA 
class II. 
Pre-specified subgroup analyses of data collected in the MADIT-CRT, REVERSE and 
Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT) trials 
demonstrated that patients with a QRS duration ≥150 ms benefited most from CRT.[47-49] 
Meta-analyses using aggregate data from randomized 
trials showed that CRT was effective in reducing adverse clinical events in patients with 
baseline QRS duration ≥150 ms and suggested that CRT might not reduce events in 
patients with a QRS <150 ms.[51] 
Indications to CRT 
There is strong evidence that CRT reduces mortality and hospitalization, improves cardiac 
function and structure in symptomatic chronic HF patients with optimal medical treatment, 
severely depressed LVEF (i.e. 
≤35%) and complete LBBB. In these patients, CRT was superior either to optimal medical 
therapy or to ICD alone. In these patients, further research is very unlikely to change our 
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confidence in the estimate of effect. Current European recommendations are displayed in 
Figure 2. 
There is no evidence of benefit in patients with HF and QRS <120 ms. In the Cardiac 
REsynchronization THerapy IN Patients with Heart Failure and Narrow QRS (RethinQ) 
trial,[52] CRT did not improve peak oxygen consumption (primary endpoint) or quality of 
life in the subgroup of patients with QRS <120 ms and evidence of echocardiographic 
dyssynchrony. The study was of too short a duration to observe effects on morbidity and 
mortality. The recent randomized, double-blind Evaluation of Resynchronization Therapy 
for Heart Failure in Patients with a QRS Duration Lower Than 120 ms (LESSER-EARTH) 
trial,[53] which compared active vs. inactive CRT therapy, was prematurely interrupted due 
to futility and safety concerns after 85 patients were randomized. Indeed, CRT was 
associated with a significant reduction in the 6-minutewalk distance and a non-significant 
trend towards an increase in heart failure-related hospitalizations. 
In conclusions, clinical factors influencing the likelihood to respond to CRT are presented 
in Figure 3.  
 
CRT-D or CRT-P? 
Previous randomized multicentre clinical studies evaluated the effect of CRT-D or CRT-P 
vs. medical therapy on all-cause mortality in patients with advanced HF (NYHA functional 
class III or IV symptoms).[45] The COMPANION trial investigated CRT-D implantation vs. 
optimal medical therapy and CRT-P implantation vs. optimal medical therapy; however, 
the trial was neither designed, nor powered to compare the effect of CRT-D vs. CRT-P 
implantation on all-cause mortality, and therefore does not provide conclusive data for the 
clinician.[44] The Cardiac Resynchronization Heart Failure (CARE-HF) trial compared 
CRT-P implantation with standard medical therapy and showed a significant mortality 
reduction in advanced heart failure patients with an implanted CRT-P. Furthermore, in the 
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extended follow-up of patients enrolled in CARE-HF, the authors demonstrated that 
patients implanted with a CRT-P alone derived a significant reduction in the risk for 
SCD.[14] Several other studies have shown that CRT alone reduces the risk of ventricular 
tachyarrhythmias and SCD due to LV reverse remodelling17 and as a result of the 
beneficial effects of CRT on the neurohormonal system.[54] This brings into question 
whether improvements in cardiac function and in the neurohormonal status resulting from 
CRT-P alone can sufficiently lower the risk of ventricular tachyarrhythmias such that the 
incremental benefit from CRT with defibrillator therapy would be of limited value. This may 
be the reason why several meta-analyses comparing the efficacy of CRT-D over CRT-P in 
patients with a primary indication for CRT have failed to show an incremental benefit of 
adding defibrillation therapy to CRT.[54-57] The risk of ventricular arrhythmias and SCD 
may be sufficiently reduced with CRT-P alone. Furthermore, CRT-D devices have a 
significantly higher cost and their widespread use remains limited especially in emerging 
countries that have fixed budgets for healthcare and where healthcare utilization is based 
on cost–benefit analysis. In addition, the complex design of defibrillator leads presents 
additional challenges including a higher risk of lead failure in the CRT-D systems.[58] 
Despite these great concerns, there is currently no consensus on in which patients CRT-P 
alone could be considered. The physician needs to estimate costs, benefit, and risks 
based on the individual patients. Clinicians in many countries face challenges in 
reimbursement of CRT devices, and expected future healthcare reforms will lead to 
additional scrutiny of expensive medical device therapies.[59] 
Until clinical guidelines or consensus statements become available, our results may help 
clinicians identify patients in whom CRT-P alone may be sufficiently effective in reducing 
adverse outcomes. 
Kutyifa et al. suggesteed that CRT-D does not have an incremental benefit over CRT-P in 
the reduction of all-cause mortality in non-ischaemic patients.[60] Only patients with 
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ischaemic aetiology of cardiomyopathy showed a significant reduction in mortality with an 
implanted CRT-D as compared with a CRT-P. The reason for this finding may be that 
patients with non-ischaemic cardiomyopathy are known to be at a lower risk for ventricular 
tachyarrhythmias particularly in the setting of CRT-induced reverse remodelling. They 
found a significantly higher risk of all-cause mortality in patients with ischaemic 
cardiomyopathy compared with non-ischaemic cardiomyopathy, and this difference in the 
mortality risk may be due to the higher risk of life-threatening ventricular arrhythmias and 
SCD in ischaemic patients. This might also explain the incremental benefit of CRT-D over 
CRT-P in ischaemic cardiomyopathy patients. CRT-D is providing incremental benefit by 
reducing the risk of SCD and all-cause mortality in patients with ischaemic 
cardiomyopathy. The European CRT survey evaluated baseline clinical characteristics[5] 
and outcome[15] of 2438 CRT patients with or without an ICD from 13 European countries 
between November 2008 and June 2009. In this survey, patients implanted with a CRT-D 
were younger, they were more often male, and they more often had ischaemic aetiology of 
cardiomyopathy and less often AF. The outcome data from the European CRT survey 
suggested that all CRT-D patients had better survival compared with CRT-P patients 
during short-term, 1-year (9–15 months) follow-up.[15] Differences in the clinical 
characteristics such as a higher percentage of ischaemic patients and an older age in the 
European CRT registry may explain the different findings between these studies. However, 
this needs further evaluation because currently older patients are more likely to be 
implanted with a CRT-P device. Another important observation is that there was a similar 
improvement in LV function in patients implanted with a CRT-D vs. a CRT-P.[60] This 
further underlines that since the improvement in cardiac function is the same in CRT-D 
and CRT-P, therefore the all-cause mortality in ischaemic and non-ischaemic patients may 
be equally related to heart failure-related death, but there is a difference in SCD-related 
death. However, patients with non-ischaemic cardiomyopathy had greater improvement in 
× 13 
LVEF than those with ischaemic cardiomyopathy. This phenomenon is well known and 
might be explained by the larger amount of scar tissue and lower contractile reserve in 
ischaemic patients that is not reversible by CRT.[61] Along this line, we might speculate 
that CRT-D may provide an incremental mortality benefit over CRT-P in those who are at a 
higher risk for SCD at implantation (e.g. ischaemic aetiology), or in those who have less 
pronounced LV reverse remodelling from CRT. 
It is important to note that patients implanted with a CRT-P alone did not have an 
increased risk of mortality compared with those with a CRT-D. The mortality risk was equal 
to that of those with an implanted CRT-D, with HRs and P-value close to 1, indicating a 
neutral effect.  
. 
Why do not patients respond to CRT?  
Up to 30-50% of patients do not benefit significantly from this therapy [62]. Non-response 
may be due to underlying cardiomyopathy, type of ventricular conduction delay (LBBB vs 
non-LBBB), suboptimal medical therapy, ineffective biventricular pacing in atrial fibrillation, 
sub-optimal position of LV lead or device programming [63-66]. Duration of QRS interval 
≥120 ms was the inclusion criterion used in most RCTs. Subgroup analysis, in a recent 
meta-analysis evaluating the impact of QRS duration on the efficacy of CRT, has shown 
that, in NYHA class III–IV HF patients, CRT significantly reduced all-cause mortality or 
hospitalization in patients with QRS duration ≥150 ms (data extracted from COMPANION 
and CARE-HF).[35] The magnitude of effect and certainty of benefit declined with shorter 
QRS duration. Furthermore, most patients in the RCTs had LBBB morphology, which was 
associated with a more pronounced benefit, compared with non-LBBB patients.[63] The 
relationship between QRS duration and morphology requires further exploration. 
Sub-group analyses based on QRS morphology in the MADIT-CRT, RAFTand REVERSE 
trials,[33,47,50,67] and a meta-analysis of COMPANION, CARE-HF, MADIT-CRT and 
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RAFT,[36] suggested that patients with complete LBBB showed a greater benefit on the 
composite of morbidity/mortality from CRT, compared with patients with non-specific IVCD 
or RBBB. Whether this is also true when applied to the effect on mortality is uncertain. 
Also, patients with LBBB had longer QRS duration,and therefore analyses by morphology 
may be confounded by QRS duration. In particular, the MADIT-CRT trial showed that, in 
patients with LBBB, CRT-D reduced by 53% the risk of death or HF hospitalization, 
compared with ICD alone, whereas non-LBBB patients did not derive clinical benefit from 
CRT therapy (statistically not significant 24% increased risk).[33] With the exception of 
NYHA functional class I, all the pre-specified subgroups based on age, QRS duration ≥150 
ms, LV volumes and LVEF showed consistent results that indicated a clinical benefit of 
CRT-D compared with ICD-only therapy in all subgroups of LBBB patients. In the non-
LBBB patients, there was no evidence of clinical benefit from CRT-D, regardless of the 
subgroup evaluated. Similar results were observed in the RAFT and REVERSE 
trials.[50,67] Based on this evidence, current class I recommendations were restricted to 
patients with complete LBBB. 
Aim of the study 
Recently Strauss et al. [64-66,68-71] proposed new stricter criteria to define a “true-LBBB”, 
with the purpose of identifying more precisely patients responder to CRT. 
Aim of the present study was to assess the rate of echocardiographic and clinical 
response to CRT in patients with LBBB according to AHA (traditional LBBB) and to 
Strauss’ criteria (strict LBBB). 
 
METHODS 
Study Population  
This study is a sub-analysis of the CRT MORE study, an observational study aimed at 
identifying predictors of response to CRT, whose design has been published previously 
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[72]. The analysis focused on a group of  consecutive patients who underwent CRT 
implantation according to 2010 ESC guidelines [73]. Patients with no-LBBB QRS 
morphology, atrial fibrillation, right bundle branch block and right ventricular pacing were 
excluded. Baseline clinical characteristics and 12-lead ECG were collected. Patients were 
classified into two groups: traditional LBBB and strict LBBB, as previously described [74]. 
The study was approved by the institutional review board, and all patients gave their 
written informed consent.  
12-lead ECG 
A standard ECG was performed in all subjects in the supine position during quiet 
respiration, at a paper speed of 25 mm/s and 50 mm/s and at a standard gain of 1 mV/cm. 
ECG parameters were independently analyzed and measured by 2 observers (F.M., A.B.): 
in case of disagreement a third observer (E.B.) was consulted. Traditional LBBB was 
defined according to the guidelines of American Heart Association (AHA)/American 
College of Cardiology Foundation (ACCF)/Heart Rhythm Society (HRS) published in 2009 
[63]: 1) QRSd ≥120 msec; 2) delayed intrinsecoid deflection in leads I, V5, V6 ≥50 msec, 
3) slurred R-waves in I, aVL, V5 and V6, 4) rS or QS waves in V1 through V2, 5) ST-T 
wave vectors opposite the main QRS vector, 6) absent Q in V5-V6. Strict LBBB was 
defined as QRSd ≥140 msec (men), QRSd ≥130 msec (women), QS or rS in V1-V2,  mid-
QRS notching or slurring in ≥ 2 contiguous leads (V1, V2, V5, V6, I and aVL) according to 
Strauss [64] (Figure 4). 
Echo 
The echocardiographic evaluation included the assessment of left ventricular end-diastolic 
volume (LVEDV), left ventricular end-systolic volume (LVESV), and LVEF assessed by 
Simpson’s equation with the apical 4-chamber view and evaluation of the severity of mitral 
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regurgitation with color Doppler in the apical 4-chamber view.  
Implantation procedure 
In all patients enrolled in the Registry, devices and pacing leads were implanted by means 
of standard techniques and all devices were programmed in accordance with the clinical 
practice of each center. Transvenous LV pacing was obtained in all patients by positioning 
the lead in a coronary sinus branch. Coronary sinus branch selection and final LV lead 
positioning were left to the discretion of the implanting physician. The right appendage and 
RV apex or septum were suggested sites for atrial and RV stimulation. 
Follow-up 
All patients were routinely seen every 6 months up to 2 years after device implantation. 
The minimum follow-up duration was of 12 months. The following data were collected at 
the baseline and at scheduled visits: patient’s history, medication use, physical 
examination results, ECG, device interrogation data and transthoracic echocardiographic 
measures. 
End points  
The primary end-points of the study were: 1) echocardiographic response to CRT, defined 
as a relative decrease of at least 15% in LVESV observed at 12-month follow-up for 
surviving patients, otherwise the last observation was carried forward [72]; 2) clinical 
response, defined as “improved” clinical composite score at 12-month follow-up [72]. In 
detail, on 12-month follow-up evaluation, patients were classified according to a score 
which assigns subjects to 1 of 3 response groups – improved, worsened, or unchanged. 
Patients were judged to have worsened if they died or were hospitalized because of 
worsening HF (at any time during the 12 months), or displayed worsening in New York 
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Heart Association (NYHA) functional class at their 12-month visit. Patients were judged to 
have improved if they had not worsened, and had displayed improvement in NYHA 
functional class at 12 months. Patients who had neither worsened nor improved were 
classified as unchanged [75]. 
Secondary end point was the cumulative survival from death or cardiovascular 
hospitalization. 
Statistical analysis 
 Results are summarized as mean (±SD) or median (25%, 75% quartiles) for 
continuous variables, and as n (%) for categorical variables. Categorical differences 
between groups were evaluated by the χ2-test or the Fisher's exact test, as appropriate. 
Continuous variables were compared with the Student’s t-test or Mann–Whitney test, as 
appropriate. Univariate and multivariate logistic regression analysis were performed to 
identify variables associated with the echocardiographic response to CRT. All variables 
associated with a statistical significance such as P<0.1 were considered for multivariate 
analysis. The cumulative probability of death or cardiovascular hospitalization was 
displayed by the method of Kaplan-Meier and using the log-rank test to compare 
cumulative events. A value of P<0.05 was considered significant. Statistics were analyzed 
with SPSS version 17 (SPSS Inc. Chicago, IL, USA).  
RESULTS 
A total of 335 patients met inclusion criteria for the analysis and had complete follow-up 
data for the assessment of the echocardiographic and clinical outcome. Patients were 
classified according to QRS morphology in 2 groups: traditional LBBB (204 patients, 61%) 
and strict LBBB (131 patients, 39%). Baseline clinical characteristics and 
echocardiographic findings of the overall population are summarized in Table 1. Baseline 
QRS duration resulted significantly larger in strict LBBB patients (166±20 msec vs 152±25 
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msec, p < <0.001). Mid-QRS notching in ≥ 2 leads was found in 51/204 (25%) traditional 
LBBB patients and in 122/131 (93%) strict LBBB patients (p<0.0001). Mid-QRS notching in 
≥1 lead was present in 101/204 (49%) traditional LBBB patients and in 127/131 (97%) 
strict LBBB patients (p<0.0001). Mid-QRS notching was more frequently present in the 
following leads : 126 in V5 (38%), 124 in V6 (37%), 110 in D1 (34%), 58 in aVL (17%), 23 
in V2 (7%), and 20 in V1 (6%). 
Follow-up.  
The length of follow-up was 365±83 days. Of the 335 patients included in analysis, 
164 (49%) displayed an improvement in their HF clinical composite response at 12 
months, 51 (15%) were classified as worsened and the remaining 120 (36%) as 
unchanged. At 12-month echocardiographic evaluation, 205 patients (61%) showed a 
decrease in LVESV ≥15% and were classified as responders. During the study period, 21 
patients died and 28 were hospitalized for cardiovascular reasons. The combined end-
point of death or cardiovascular hospitalization was reached by 46 (14%) patients.  
Predictive value of QRS morphology. 
The clinical composite response and the echocardiographic response were comparable at 
12-month visit in the 2 groups (Table 2 and 3). The survival curves for death or 
cardiovascular hospitalization were calculated and no significant differences emerged 
between groups (log-rank test, p=0.827) (Figure 5). 
Univariate and multivariate analysis of factors associated with echocardiographic response 
are listed in Table 4. At multivariate analysis history of atrial fibrillation (OR 0.424; 95% CI 
0.216 to 0.833, p=0.001), larger end systolic left ventricular volume (OR 1.007; 95% CI 
1.002 to 1.012, p=0.012) and presence of mid-QRS notching in at least 1 lead (OR 1.959; 
95 % CI 1.039 to 3.695, p=0.038) were independently associated with the 




Main finding. Recently proposed stricter criteria for LBBB diagnosis did not improve the 
identification of CRT responders. Among ECG variables, only the presence of mid-QRS 
notching in at least 1 lead was associated with the echocardiographic response. 
Definition of LBBB: the “clinical problem” 
Since LBBB morphology seems highly predictive of a positive CRT response, careful 
analysis of the baseline ECG is of great value to improve the selection of patients. 
However, identifying complete LBBB on the 12-lead ECG is not as straightforward as one 
might presume. In fact, definition of LBBB differs between current guidelines [31,32] and 
among clinical trials.[19,34,51] Recently, Strauss et al. suggested to include mid-QRS 
notch/slurring in ≥ 2 contiguous leads (V1, V2, V5, V6, I and aVL), which seems necessary 
to distinguish true complete LBBB from a combination of LV hypertrophy, LV dilatation and 
incomplete LBBB, regarded as LBBB using conventional criteria.[64]  
These stricter criteria, if adopted, reduce the number of patients candidate to CRT. Among 
158 patients diagnosed with LBBB according to the automated Glasgow criteria, the 
manual application of Strauss criteria confirmed the diagnosis of LBBB in 87% of the 
patients.[76] Our findings, that is a prevalence of strict LBBB in 39% of our population, are 
closer to the experience of Mascioli et al. [71]: among 111 patients with LVEF ≤ 35% and 
LBBB morphology who received a CRT device, only 55% presented with a “true” LBBB 
morphology. The choice to implant only this very selected population could exclude a 
significant number of potential responders to CRT. 
Predictive value of QRS morphology 
Published data showing that better response to CRT is associated with a “true” LBBB, 
derived from small studies. [70,71]. Mascioli et al.compared echocardiograpich and clinical 
outcome 816 ± 517 days after CRT implant of 111 patients with true LBBB (61 patients) 
and “false” LBBB (50 patients), according to the presence or not of the notch  in ≥ 2 leads 
× 20 
among I, aVL, V1, V2, V5, V6. The “false” LBBB and a low dose of bisoprolol at the last 
follow-up  correlated with a bad prognosis (death or hospitalization for heart failure), while 
only the “true” LBBB correlated with an increase ≥ 10% of left ventricular ejection 
fraction.[71] Tian et al. found that left ventricular ejection fraction increased significantly 
after CRT only in 22 patients with “true” LBBB, but not in 17 with “not true” LBBB, and in 
19 patients with non-specific intraventricular delay.[70] 
Our findings, obtained from a large cohort of patients enrolled in 31 different Centers, did 
not confirm previous results. CRT performed well in term of clinical composite response 
and echocardiographic response at 12-month both in patients with strict LBBB and in 
patients with traditional LBBB. At the multivariate analysis, along with sinus rhythm and a 
large end systolic left ventricular volume at enrollment, the presence of mid-QRS notching 
in at least 1 lead predicted a favorable outcome of CRT. In the vast majority of our 
patients, mid-QRS notching was recorded in the leads which explored the lateral wall of 
the left ventricle (I, aVL, V5 and V6). The presence of  mid-QRS notching in these leads 
might be sufficient to identify patients with a delayed conduction along the left lateral 
ventricular wall who could benefit from CRT. 
Conclusions 
The presence of mid-QRS notching in at least 1 lead identifies patients with an 
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Table 1. Demographic data, baseline clinical parameters and pharmacological treatment. 






Male gender, n (%) 153 (75) 88 (67) 0.120 
Age, years 69±10 70±9 0.364 
Body Mass Index 26±6 26±7 0.677 
Ischemic etiology, n (%) 86 (42) 56 (43) 0.915 
History of atrial fibrillation, n (%) 53 (26) 33 (25) 0.872 
QRS duration, ms 152±25 166±20 <0.001 
PR duration, ms 189±50 187±44 0.732 
NYHA class 
- Class II, n (%) 










Diabetes, n (%) 62 (30) 43 (33) 0.640 
COPD, n (%) 38 (19) 29 (22) 0.433 
Chronic kidney disease, n (%) 49 (24) 39 (30) 0.243 
Hypertension, n (%) 119 (58) 82 (63) 0.437 
LV ejection fraction, % 28±6 29±6 0.297 
LVEDV, ml 195±87 198±71 0.813 
LVESV, ml 143±74 143±58 0.982 
Moderate to severe mitral regurgitation, 
n (%) 
170 (83) 98 (75) 0.057 
CRT-D device, n (%) 184 (90) 114 (87) 0.366 
-Blocker use, n (%) 163 (80) 109 (83) 0.450 
ACE-inhibitor use, n (%) 111 (54) 72 (55) 0.921 
Diuretic use, n (%) 171 (84) 110 (84) 0.972 
Class III antiarrhythmic use, n (%) 44 (22) 24 (18) 0.471 
Ivabradine, n (%) 18 (9) 7 (5) 0.237 
LV lead position: Basal 42 (21) 30 (23) 0.615 
LV lead position: Mid 143 (70) 88 (67) 0.573 
LV lead position: Apical 18 (9) 13 (40) 0.735 
LV lead position: Anterior 10 (5) 3 (2) 0.227 
LV lead position: Lateral 192 (94) 125 (96) 0.606 







NYHA = New York Heart Association; COPD = Chronic obstructive pulmonary disease; LV = Left ventricular; 
LVEDV = Left ventricular end-diastolic volume; LVESV = Left ventricular end-systolic volume; CRT-D = 
Cardiac resynchronization therapy defibrillator; ACE = Angiotensin-converting-enzyme. 
× 32 
Table 2. Classification of study population according to HF clinical composite response at 12-month visit. 
 
 Traditional LBBB 
(n=204) 
Strauss LBBB  (n=131) p 
Improved, n (%) 93 (46) 71 (54) 0.124 
Unchanged, n (%) 78 (38) 42 (32) 0.250 




Table 3. Classification of study population according to echocardiographic response at 12-month visit. 
 
 
Traditional LBBB  
(n=204) 
Strauss LBBB  
(n=131) 
p 
Responder, n (%) 120 (59) 85 (65) 
0.267 
Non responder, n (%) 84 (41) 46 (35) 
Table 4. Univariate and multivariate analyses of factors associated with the echocardiographic end-point. 
 Univariate analysis Multivariate analysis 
 Odds ratio 95% CI p Odds ratio 95% CI P 
Age 0.985 0.956 to 1.015 0.319 - - - 
Male gender 0.569 0.297 to 1.088 0.082 0.604 0.296 to 1.221 0.160 
Ischemic aetiology 0.673 0.384 to 1.180 0.167 - - - 
History of AF 0.327 0.172 to 0.621 0.001 0.424 0.216 to 0.833 0.013 
QRS duration 1.003 0.992 to 1.015 0.542 - - - 
PR duration 1.000 0.993 to 1.007 0.940 - - - 
NYHA Class (II) 1.403 0.792 to 2.484 0.244 - - - 
Hypertension 0.856 0.490 to 1.496 0.585 - - - 
Diabetes 0.842 0.463 to 1.534 0.575 - - - 
COPD 0.902 0.445 to 1.826 0.774 - - - 
Chronic kidney disease 0.678 0.361 to 1.273 0.228 - - - 
Echocardiographic findings    - - - 
LVEF 0.975 0.935 to 1.018 0.247 - - - 
LVEDV 1.004 1.000 to 1.008 0.024 - - - 
LVESV 1.006 1.001 to 1.011 0.011 1.007 1.002 to 1.012 0.012 
LVEDD 0.991 0.960 to 1.023 0.573 - - - 
LVESD 0.999 0.972 to 1.027 0.951 - - - 
× 35 
Severe MR 0.678 0.390 to 1.177 0.167 - - - 
Pharmacologic treatment    - - - 
ACE/ARB 1.715 0.910 to 3.231 0.096 1.332 0.662 to 2.682 0.422 
Diuretics 0.943 0.455 to 1.954 0.874 - - - 
Statin 0.889 0.510 to 1.549 0.677 - - - 
Beta-blockers 1.967 0.923 to 4.187 0.079 1.726 0.747 to 3.986 0.201 
Ivabradyn 1.301 0.429 to 3.947 0.638 - - - 
Antiarrhythmics 1.068 0.249 to 4.588 0.930 - - - 
Notch _1 lead (at least) 2.104 1.168 to 3.790 0.013 1.959 1.039 to 3.695 0.038 
Notch_2 lead (at least) 1.599 0.925 to 2.767 0.092 - - - 
Notch_2 contiguous lead 1.391 0.802 to 2.415 0.239 - - - 
Apical lead positioning 1.417 0.552 to 3.632 0.462 - - - 
Lateral lead positioning 1.046 0.359 to 3.053 0.934 - - - 
 
AF = atrial fibrillation; COPD = Chronic obstructive pulmonary disease; LVEF = left ventricular ejection fraction; LVEDV = left ventricular end diastolic volume; 
LVESV= left ventricular end sistolic volume; LVEDD = left ventricular end diastolic diameter; LVESD = left ventricular end sistolic diameter; MR = mitral 
regurgitation. 
FIGURES 
Figure 1: Inclusion criteria, design, endpoints, and main findings of the randomized clinical trials 













Figure 4: Typical ECG features of Traditional LBBB according to AHA definition (a) and 
Strict  LBBB according to Strauss (b). Of note, the presence of mid-QRS notching in lateral 
leads (circles) in LBBB according to Strauss, lacking in traditional LBBB. 
 
× 40 
Figure 5: survival curves for death or cardiovascular 
hospitalization.
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Overall long-rank test: p=0. 8273 
× 41 
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ORGANIZZATIVE   
. 
  Dirigente medico di I livello di Cardiologia dal 6 agosto 1997, nel corso degli 
anni ha sviluppato, oltre a competenze generali nell’ambito della disciplina di 
Cardiologia, competenze specifiche nel campo dell’Aritmologia, in particolar 
modo dell’elettrofisiologia, dell’ablazione trans catetere delle aritmie, della 
cardiostimolazione, della gestione del paziente con scompenso cardiaco 
cronico.  
 In qualita’ di direttore f.f. dell’U.O.C. di Cardiologia del P.O. di Mirano nel corso 
del 2007 ha partecipato all’istituzione della rete  cardiologica regionale veneta 




per la gestione dell’infarto miocardico acuto, e ha gestito l’organizzazione di 
questa attivita’ per le ULSS 13 e 14. 
 in qualita’ di responsabile dell’U.O.S. a valenza dipartimentale di 
elettrofisiologia, elettrostimolazione e scompenso cardiaco,  ha gestito in prima 
persona l’ambulatorio per lo scompenso cardiaco del P.O. di Mirano dal 1 
aprile 2009 al 31 agosto 2012, ponendo particolare attenzione 
all’organizzazione delle cure per il paziente affetto da scompenso cardiaco 
cronico, creando un sistema integrato con l’U.O.C. di Medicina e la rete dei 
medici di Medicina Generale. Ha favorito, tra i primi all’interno della regione 
veneto, l’introduzione di sistemi di telemedicina per la gestione domiciliare del 
paziente con aritmie e del paziente con scompenso cardiaco cronico, 
mediante la rilevazione a distanza di elettrocardiogramma, pressione arteriosa 
e peso corporeo. (vedi allegati 17, 82, 83, 94, 100) Ha validato l’efficacia della 
telemedicina nel paziente con scompenso cardiaco cronico partecipando alla 
Ricerca Finalizzata della Regione Veneto 2006 per la “Realizzazione di un 
modello di integrazione tra Ospedale e territorio con utilizzo di strumentazioni 
informatiche e reti telematiche per il monitoraggio a domicilio dello scompenso 
cardiaco; Cluster 7 del progetto Renewing Health”.                                                                                 
 Dal 25 maggio 2007, come responsabile prima dell’U.O.S. di elettrofisiologia 
ed elettrostimolazione e poi dell’U.O.S.  a valenza dipartimentale di 
elettrofisiologia, elettrostimolazione e scompenso cardiaco, ha introdotto 
all’interno del P.O. di Mirano l’utilizzo del controllo remoto dei dispositivi 
impiantabili, diventando un punto di riferimento nazionale su tale materia, 
come testimoniato dalle numerose  partecipazioni a congressi in qualita’ di 
relatore sull’argomento (vedi allegati 81, 85, 87, 89, 106). 
 In qualita’ di direttore f.f. dell’U.O.C. di Cardiologia del P.O. di Mirano, ha 
gestito dal 1 giugno 2007 al 30 aprile 2008 un reparto dotato di 44 posti letto, 
di cui 8 di utic, 32 di degenza ordinaria, e 4 di day-hospital:  
o Acquisendo esperienza nella gestione del personale; 
o Delegando i colleghi nella conduzione delle varie attivita’ di reparto 
(emodinamica, elettrofisiologia, terapia intensiva cardiologica, 
imaging cardiovascolare); 
o Consentendone  l’aggiornamento professionale costante; 
o Favorendo l’autonomia tecnico-professionale del personale 
infermieristico e tecnico; 
o Creando un buon clima lavorativo cercando di appianare i conflitti 
interni. 
 In qualita’ di Presidente del Consiglio Direttivo Veneto dell’Associazione 
Italiana di Aritmologia e Cardiostimolazione ha favorito la creazione di sistemi 
“hub & spoke” per la gestione delle urgenze aritmologiche (trattamento dello 
storm artimico ed estrazione di elettrocateteri impiantati infetti o 
malfunzionanti). (vedi allegato 84). A tal proposito, nel corso del 2014 e’ stato 
chiamato dall’area sanita’ e sociale della regione veneto a far parte del gruppo 
tecnico per la realizzazione del “modello assistenziale di rete cardiologica per 
la diagnosi e terapia nei confronti di pazienti affetti da aritmia e scompenso 
cardiaco” (vedi allegato 107). 
 In qualita’ di Presidente del Consiglio Direttivo Veneto dell’Associazione 
Italiana di Aritmologia e Cardiostimolazione ha partecipato alla realizzazione 
del documento di “Health Techonolgy Assessment AIAC sull’ablazione della 
fibrillazione atriale” (vedi allegato 64).  
 
CAPACITÀ E COMPETENZE 
TECNICHE 
. 
  Ablazione trans catetere di fibrillazione atriale, aritmie reciprocanti SV e 
ventricolari come primo operatore: 1228 
 Studio elettrofisiologico di aritmie sopraventricolari e ventricolari come primo 
operatore: 152 
 Applicazione di pacemaker e/o defibrillatore impiantabile con o senza sistema 
× 53 
di resincronizzazione come primo operatore: 891 
 Applicazione di ICD sottocutaneo come primo operatore: 2 
 Sostituzione di pacemaker e/o defibrillatore impiantabile come primo 
operatore: 239 
 Riposizionamento di elettrocateteri cronicamente impiantati per stimolazione 
e/o defibrillazione e/o revisione tasca come primo operatore: 29  
 Estrazione di elettrocateteri cronicamente impiantati per stimolazione e/o 
defibrillazione come primo operatore: 36 
 Controllo elettronico di pacemaker e/o defibrillatore impiantabile come primo 
operatore:1399 
Accanto all’attività assistenziale, nel campo dell’Aritmologia e in particolare 
dell’Aritmologia Interventistica, ha condotto numerose ricerche cliniche su: 
 Modificazioni cardiovascolari indotte dall’ipossia d’alta quota (vedi allegato 1) 
 Basi morfologiche delle aritmie sopraventricolari e ventricolari (vedi allegato 2, 
5, 9, 42, 55) 
 Prevenzione della morte improvvisa (vedi allegato 54) 
 Trattamento farmacologico della fibrillazione atriale (vedi allegato 7, 11, 20, 
21) 
 Effetti clinici della terapia di resincronizzazione cardiaca (vedi allegato 36, 38, 
69, 70, 72, 78, ) 
 Ablazione della fibrillazione atriale (vedi allegati 12, 18, 26, 35, 37, 39, 41, 68, 
73, 74, 75, 79, 91) 
 Investigatore principale del registro multicentrico triveneto sull’ablazione del 
flutter atriale (vedi allegato 15, 16) 
 Membro dello Steering Committee dello studio multicentrico nazionale “A 
prospective, randomised, controlled study on effect of catheter ablation for the 
cure of atrial fibrillation (Catheter Ablation for the Cure of Atrial Fibrillation 
Study)” (vedi allegato 21) 
 Investigatore Principale dello studio multicentrico internazionale “A Clinical and 
Health-Economic Evaluation of Pulmonary Vein Encirculation Compared to 
Antiarrhythmic Drug Treatment in Patients with Persistent Atrial Fibrillation 
(Catheter Ablation for the Cure of Atrial Fibrillation – 2 Study)” (vedi allegato 
27) 
 Membro dello Steering Committee dello studio multicentrico nazionale EPASS 
(cardiostimolazione) (vedi allegato 42) 
 Investigatore principale del registro multicentrico nazionale CARTOMERGE 
(ablazione della fibrillazione atriale) (vedi allegato 34) 
 Membro dello Steering Committee dello studio multicentrico nazionale 
CRT_MORE (re sincronizzazione cardiaca) (vedi allegato 72) 
 
Ha iniziato dal 2005 ad utilizzare il sofisticato sistema di integrazione delle immagini nel 
sistema di mappaggio elettroanatomico Carto-Merge, diventandone uno dei maggiori 
esperti a livello europeo (vedi allegati 32, 34). 
 
Ha fatto parte della Task-force che ha redatto le Linee guida AIAC 2010 per la gestione 
e il trattamento della fibrillazione atriale (vedi allegati 63, 65) 
 
In qualità di responsabile dell’U.O.S. di Aritmologia Interventistica dell’Azienda 
Ospedaliera di Padova ha favorito la realizzazione di interventi ibridi in collaborazione 
con i Cardiochirurghi per il trattamento della fibrillazione atriale, delle aritmie ventricolari 












 Spedizione scientifica Ev-K2-CNR organizzata dall’Università di Padova in 
collaborazione con il CNR al campo base del monte Everest (Nepal), per studiare le 




Settembre -Ottobre 1990 
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ATTIVITA’ DIDATTICA  Insegnamento di Semeiotica delle valvulopatie al 1° anno della Scuola di 
Specializzazione in Malattie dell’apparato cardiovascolare dell’Università degli Studi di 
Padova (vedi allegato 117) 
 
ASSOCIAZIONI   Presidente del Consiglio Direttivo Regionale Veneto della Associazione Italiana 
Cardiologia ed Elettrostimolazione dall’aprile 2010 a marzo 2014 
 Segretario del Consiglio Direttivo Nazionale della Associazione Italiana Cardiologia 
ed Elettrostimolazione da marzo 2014 
 
 
   
 
 
Autorizzo il trattamento dei miei dati personali ai sensi del D.lgs. 196 del 30 giugno 2003. 
 
30 gennaio 2016                                                                Emanuele Bertaglia 
 
 
 
 
 
